Bibliography
- Rhee CW , LeeJ, OhS, ChoiNK, ParkBJ. Use of bisphosphonates and risk of atrial fibrillation in older women with osteoporosis. Osteoporosis Int. (2011) (Epub ahead of print).
- Kannel WB , BenjaminEJ. Status of the epidemiology of atrial fibrillation. Med. Clin. N. Am.92 , 17–40 (2008).
- Benjamin EJ , LevyD, VaziriSM, D‘AgostinoRB, BelangerAJ, WolfPA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham heart study. JAMA271 , 840–844 (1994).
- Falk RH . Atrial fibrillation. N. Engl. J. Med.344 , 1067–1078 (2001).
- Go AS , FangMC, UdaltsovaN et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 119 , 1363–1369 (2009).
- Psaty BM , ManolioTA, KullerLH et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 96 , 2455–2461 (1997).
- Ruo B , CapraAM, JensvoldNG, GoAS. Racial variation in the prevalence of atrial fibrillation among patients with heart failure: the epidemiology, practice, outcomes, and costs of heart failure (EPOCH) study. J. Am. Coll. Cardiol.43 , 429–435 (2004).
- Tanko LB , ChristiansenC, CoxDA, GeigerMJ, McnabbMA, CummingsSR. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J. Bone Miner. Res.20 , 1912–1920 (2005).
- Black DM , DelmasPD, EastellR et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356 , 1809–1822 (2007).
- Lyles KW , Colon-EmericCS, MagazinerJS et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N. Engl. J. Med. 357 , 1799–1809 (2007).
- Cummings SR , SchwartzAV, BlackDM. Alendronate and atrial fibrillation. N. Engl J. Med.356 , 1895–1896 (2007).
- Cummings SR , BlackDM, ThompsonDE et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 280 , 2077–2082 (1998).
- Karam R , CammJ, McClungM. Yearly zoledronic acid in postmenopausal osteoporosis. N. Engl. J. Med.357 , 712–713 (2007).
- Heckbert SR , LiG, CummingsSR, SmithNL, PsatyBM. Use of alendronate and risk of incident atrial fibrillation in women. Arch. Int. Med.168 , 826–831 (2008).
- Sorensen HT , ChristensenS, MehnertF et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case–control study. BMJ 336 , 813–816 (2008).
- Papapetrou PD . Bisphosphonate-associated adverse events. Hormones (Athens)8 , 96–110 (2009).
- Abrahamsen B , EikenP, BrixenK. Atrial fibrillation in fracture patients treated with oral bisphosphonates. J. Int. Med.265 , 581–592 (2009).
- Huang WF , TsaiYW, WenYW, HsiaoFY, KuoKN, TsaiCR. Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene. Menopause17 , 57–63 (2010).
- Sewerynek E , MałkowskiB, KarzewnikE et al. Alendronate 70 therapy in elderly women with post-menopausal osteoporosis: the problem of compliance. Pol. J. End. 62 , 24–29 (2011).
- Bhuriya R , SinghM, MolnarJ, AroraR, KhoslaS. Bisphosphonate use in women and the risk of atrial fibrillation: a systematic review and meta-analysis. Int. J. Cardiol.142 , 213–217 (2010).
- Mak A , CheungMW, HoRC, CheakAA, LauCS. Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies. BMC Musculoskelet. Disord.10 , 113–124 (2009).
- Sewerynek E , StussM. Bisphosphonates and risk of atrial fibrillation. Pol. J. End.62 , 93–96 (2011).
- Poole KE , ReeveJ, WarburtonEA. Falls, fractures, and osteoporosis after stroke: time to think about protection? Stroke33 , 1432–1436 (2002).
- Reid IR , BrownJP, BurckhardtP et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N. Engl. J. Med. 346 , 653–661 (2002).
- Vasikaran SD . Bisphosphonates: an overview with special reference to alendronate. Ann. Clin. Biochem.38 , 608–623 (2001).
- Kim HW , ParkCW, ShinYS et al. Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis. Nephron. Clin. Pract. 102 , c21–c29 (2006).
- Van Wagoner DR , NerbonneJM. Molecular basis of electrical remodeling in atrial fibrillation. J. Mol. Cell Cardiol.32 , 1101–1117 (2000).
- Aviles RJ , MartinDO, Apperson-HansenC et al. Inflammation as a risk factor for atrial fibrillation. Circulation 108 , 3006–3010 (2003).
- Hewitt RE , LissinaA, GreenAE, SlayES, PriceDA, SewellAK. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin. Exp. Immunol.139 , 101–111 (2005).
- Body JJ , DielI, BellR. Profiling the safety and tolerability of bisphosphonates. Semin. Oncol.31 , 73–78 (2004).